BridgeBio Pharma, Inc. announced that the FDA has accepted for filing its New Drug Application (NDA) for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1). The FDA has assigned a PDUFA target action date of May 8, 2027, and the company is preparing to launch the therapy upon approval. BridgeBio is also planning to submit a Marketing Authorization Application (MAA) to the EMA in the second half of 2026. BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing medicines for genetic conditions.

BridgeBio Pharma, Inc. entered into an Investment Agreement on July 1, 2026, to issue and sell 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock to Chinotto Investments, LLC and HCRx Investments HoldCo, L.P. for an aggregate price of $933,900,000 at $1,000 per share. The Preferred Stock is convertible into common stock at an initial conversion price of $137.79 per share and carries a 7.00% annual dividend rate. BridgeBio Pharma, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases.